Aromatase Inhibitor Clinical Trials

4 actively recruiting trials across 2 locations

No change since May 2026

Also known as: AI, Anastrozole (Arimidex), Exemestane (Aromasin), Letrozole (Femara)

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 1

Top Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Hebei Medical University Fourth Hospital1
Finn, Olivera, PhD1
BeOne Medicines1

Indications

Breast Cancer4
Cancer4
Ductal Carcinoma in Situ1
Advanced Solid Tumor1

Other2 trials

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3

Birmingham, Alabama1 trial

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

University of Alabama At Birmingham Hospital

Phase 1

Pittsburgh, Pennsylvania1 trial

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

UPMC Magee Womens Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.